Enorama Pharma AB (SE:ERMA)

:ERMA

ERMA

Enorama Pharma AB

RESEARCH TOOLSreports

Enorama Pharma AB (ERMA) Price & Analysis

0 Followers

ERMA Stock Chart & Stats

kr1.91

-kr0.30(-12.50%)

At close: Mar 06 4:00 PM EST

kr1.91

-kr0.30(-12.50%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr3.58

Previous CloseN/A

Volume29.79K

Average Volume (3M)4.35K

Market Cap

kr26.03M

Enterprise Valuekr27.54M

Total Cash (Recent Filing)kr3.04M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.46

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding74,588,684

10 Day Avg. Volume2,975

30 Day Avg. Volume4,348

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)-5.66

Price to Sales (P/S)48.45

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageReported zero total debt across 2024–2025 keeps financial leverage very low, reducing interest burden and default risk. For a development-stage pharma, low reported debt preserves strategic optionality to seek partnerships or equity financing without heavy fixed financing costs.

Focused NRT PipelineA concentrated development program centered on NIC-101 gives the company a clear scientific and commercial focus. Specialization in nicotine replacement therapy aligns with structural demand for smoking cessation and harm-reduction solutions, supporting a coherent long-term product strategy.

Lean Operating StructureA five-person workforce implies a very lean cost base and low fixed overhead, which can extend runway versus larger peers. For a small developer, a compact team supports agile decision-making, lower cash burn on personnel, and easier outsourcing of trials or manufacturing.

Bears Say

Sharp Revenue DeclineA ~25% revenue decline in 2025 following only modest prior growth signals weak commercial traction or disrupted sales channels. Persistent top-line instability undermines internal funding for R&D and increases reliance on external financing or partnerships to advance NIC-101.

Negative Shareholders' EquityNegative shareholders' equity materially weakens the capital base and raises funding and counterparty concerns. This reduces ability to absorb further losses, makes raising new equity or debt more dilutive or costly, and may constrain partnering or supplier terms over months ahead.

Persistent Operating Cash BurnOperating cash flow has been repeatedly negative and worsened in 2025, indicating ongoing cash burn and no internal cash generation to fund operations. Continued negative cash flow increases near-term liquidity pressure and the need for financing that could dilute shareholders.

ERMA FAQ

What was Enorama Pharma AB’s price range in the past 12 months?

Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.58 in the past 12 months.

What is Enorama Pharma AB’s market cap?

Enorama Pharma AB’s market cap is kr26.03M.

When is Enorama Pharma AB’s upcoming earnings report date?

Enorama Pharma AB’s upcoming earnings report date is May 20, 2026 which is in 47 days.

How were Enorama Pharma AB’s earnings last quarter?

Enorama Pharma AB released its earnings results on Feb 18, 2026. The company reported -kr0.276 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.276.

Is Enorama Pharma AB overvalued?

According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enorama Pharma AB pay dividends?

Enorama Pharma AB does not currently pay dividends.

What is Enorama Pharma AB’s EPS estimate?

Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enorama Pharma AB have?

Enorama Pharma AB has 74,588,684 shares outstanding.

What happened to Enorama Pharma AB’s price movement after its last earnings report?

Enorama Pharma AB reported an EPS of -kr0.276 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 22.613%.

Which hedge fund is a major shareholder of Enorama Pharma AB?

Currently, no hedge funds are holding shares in SE:ERMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enorama Pharma AB

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.